{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:52:06Z","timestamp":1771879926324,"version":"3.50.1"},"publisher-location":"Chichester, UK","reference-count":130,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd005429","type":"reference-entry","created":{"date-parts":[[2005,7,4]],"date-time":"2005-07-04T13:18:45Z","timestamp":1120483125000},"source":"Crossref","is-referenced-by-count":62,"title":["Which anticholinergic drug for overactive bladder symptoms in adults"],"prefix":"10.1002","author":[{"given":"Jean","family":"Hay-Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaye","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G Peter","family":"Herbison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,7,20]]},"reference":[{"key":"10.1002\/14651858.CD005429-BIB1|cit1","series-title":"Proceedings of the International Continence Society, 26th Annual Meeting, 27-30 Aug; Athens, Greece","first-page":"276","article-title":"A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia","author":"Abrams","year":"1996"},{"key":"10.1002\/14651858.CD005429-BIB2|cit2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","article-title":"Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder","volume":"81","author":"Abrams","year":"1998","journal-title":"British Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB3|cit3","first-page":"103","article-title":"Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability (Abstract)","volume":"157","author":"Abrams","year":"1997","journal-title":"Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD005429-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0022-5347(05)68810-6","article-title":"Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence","volume":"161","author":"Anderson","year":"1999","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD005429-BIB5|cit5","series-title":"Proceedings of the International Continence Society (ICS), 31st Annual Meeting, 18-21 Sept, Seoul, Korea","article-title":"Central nervous system adverse events with anticholinergic medication for overactive bladder (Abstract 213)","author":"Anderson","year":"2001"},{"key":"10.1002\/14651858.CD005429-BIB6|cit6","series-title":"Poster session abstracts, 2nd International Consultation on Incontinence, Paris","article-title":"Randomized, double-blind study of extended-release oxybutynin and tolterodine for overactive bladder in female patients (Abstract number 71)","author":"Appell"},{"key":"10.1002\/14651858.CD005429-BIB7|cit7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","article-title":"Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT study","volume":"76","author":"Appell","year":"2001","journal-title":"Mayo Clinical Proceedings"},{"key":"10.1002\/14651858.CD005429-BIB8|cit8","series-title":"Proceedings of the International Continence Society (ICS), 31st Annual Meeting, 18-21 Sept, Seoul, Korea","article-title":"Randomized, double-blind study of controlled-release oxybutynin and tolterodine for overactive bladder (Abstract 327)","author":"Dmochowski","year":"2001"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD005429-BIB9|cit9","first-page":"42S","article-title":"Randomized double-blind study to compare two treatments for urinary frequency in women by age","volume":"99","author":"Karram","year":"2002","journal-title":"Obstetrics &Gynecology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005429-BIB10|cit10","first-page":"S44","article-title":"Randomized, double-blind study of extended-release oxybutynin and tolterodine for overactive bladder in female patients","volume":"12","author":"Miklos","year":"2001","journal-title":"International Urogynecolgy Journal"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB11|cit11","first-page":"S49","article-title":"Randomized, double-blind study to compare extended-release oxybutynin and tolterodine for overactive bladder","volume":"97","author":"Sand","year":"2001","journal-title":"Obstetrics & Gynecology"},{"issue":"Supplement 3","key":"10.1002\/14651858.CD005429-BIB12|cit12","first-page":"S71","article-title":"Central nervous system adverse events with anticholinergic medication for overactive bladder","volume":"12","author":"Sand","year":"2001","journal-title":"International Urogynecolgy Journal"},{"key":"10.1002\/14651858.CD005429-BIB13|cit13","series-title":"Proceedings of the 2nd International Consultation on Incontinence, 1-3 July, Paris","article-title":"Central nervous system adverse events with anticholinergic medication for overactive bladder (Abstract 71)","author":"Staskin","year":"2001"},{"issue":"1","key":"10.1002\/14651858.CD005429-BIB14|cit14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/00365598509180219","article-title":"Emepronium carregeenate: clinical effects and urinary excretion in treatment of female urge incontinence","volume":"19","author":"Bagger","year":"1985","journal-title":"Scandanavian Journal of Urology and Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD005429-BIB15|cit15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1464-410x.2000.00623.x","article-title":"A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin","volume":"85","author":"Birns","year":"2000","journal-title":"British Journal of Urology International"},{"issue":"5","key":"10.1002\/14651858.CD005429-BIB16|cit16","first-page":"429","article-title":"Controlled-release oxybutynin maintains efficacy with a 43% reduction in side effects compared with conventional oxybutynin treatment (Abstract)","volume":"16","author":"Birns","year":"1997","journal-title":"Neurourology and Urodynamics"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB17|cit17","first-page":"351","article-title":"A randomised cross over trial comparing oxybutynin taken three times a day or taken \"when needed\"","volume":"13","author":"Burton","year":"1994","journal-title":"Neurourology and Urodynamics"},{"issue":"Suppl 17","key":"10.1002\/14651858.CD005429-BIB18|cit18","first-page":"92","article-title":"Trospium chloride for the treatment of detrusor instability: a placebo-controlled dose-finding study (Abstract)","volume":"105","author":"Chaliha","year":"1998","journal-title":"British Journal of Obstetrics and Gynaecology"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB19|cit19","first-page":"381","article-title":"YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo and tolterodine controlled, phase II, dose-finding study","volume":"21","author":"Chapple","year":"2002","journal-title":"Neurourology and Urodynamics"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005429-BIB20|cit20","first-page":"S43","article-title":"Transdermal oxybutynin: A multi-center, prospective, randomized, double-blind, placebo-controlled study in adults with urge urinary incontinence","volume":"12","author":"Davila","year":"2001","journal-title":"International Urogynecology Journal"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB21|cit21","first-page":"426","article-title":"Transdermal oxybutynin is safe, effective, and improves quality of life in patients with overactive bladder (Abstract number 34)","volume":"20","author":"Davila","year":"2001","journal-title":"Neurourology and Urodynamics"},{"key":"10.1002\/14651858.CD005429-BIB22|cit22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-5347(05)66095-8","article-title":"A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence","volume":"166","author":"Davila","year":"2001","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD005429-BIB23|cit23","series-title":"Proceedings of the International Continence Society (ICS), 32nd Annual Meeting, 28-30 Aug, Heidelberg, Germany","article-title":"Effects of transdermal and oral oxybutynin and its metabolites on cystometrogram parameters (Abstract 220)","author":"Neimark","year":"2002"},{"issue":"2","key":"10.1002\/14651858.CD005429-BIB24|cit24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00005392-200102000-00032","article-title":"Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens","volume":"165","author":"Stasi","year":"2001","journal-title":"Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD005429-BIB25|cit25","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/S0022-5347(05)65540-1","article-title":"Intravesical oxybutynin: Mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and n-desethyl oxybutynin","volume":"166","author":"Stasi","year":"2001","journal-title":"Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD005429-BIB26|cit26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clinic Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD005429-BIB27|cit27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0090-4295(03)00356-X","article-title":"Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed incontinence","volume":"62","author":"Dmochowski","year":"2003","journal-title":"Urology"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB28|cit28","first-page":"380","article-title":"Transdermal oxybutynin and controlled release oral tolterodine in patients with positive treatment effect to anticholinergic therapy for overactive bladder (Abstract)","volume":"21","author":"Dmochowski","year":"2002","journal-title":"Neurourology and Urodynamics"},{"issue":"5","key":"10.1002\/14651858.CD005429-BIB29|cit29","first-page":"24","article-title":"Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder","volume":"Suppl 167","author":"Drutz","year":"1997","journal-title":"Acta Obstetrica et Gynecologica Scandinavica"},{"issue":"5","key":"10.1002\/14651858.CD005429-BIB30|cit30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s001929970003","article-title":"Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder","volume":"10","author":"Drutz H.","year":"1999","journal-title":"International Urogynecology Journal"},{"issue":"1","key":"10.1002\/14651858.CD005429-BIB31|cit31","first-page":"S14","article-title":"Enhanced tolerability of Tolterodine compared to Oxybutynin in a controlled clinical study (Abstract)","volume":"8","author":"Drutz","year":"1997","journal-title":"International Urogynecology Journal and Pelvic Floor Dysfunction"},{"key":"10.1002\/14651858.CD005429-BIB32|cit32","series-title":"Proceedings of the International Continence Society (ICS), 27th Annual Meeting, 23-26 Sept, Yokohama, Japan","first-page":"159","article-title":"Urodynamic effects of intravesical instillation of trospium chloride in man","author":"Froehlich","year":"1997"},{"issue":"1","key":"10.1002\/14651858.CD005429-BIB33|cit33","first-page":"486","article-title":"Intravesical trospium chloride, oxybutynin and verapamil for relaxation of detrusor muscle. A placebo-controlled, randomised clinical trial","volume":"48","author":"Frohlich","year":"1998","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/14651858.CD005429-BIB34|cit34","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0022-5347(17)45940-4","article-title":"Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia","volume":"135","author":"Gajewski","year":"1986","journal-title":"The Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB35|cit35","first-page":"487","article-title":"Tolerability and efficacy of trospium chloride in a long-term treatment (52 weeks) in patients with urge-syndrome: a double-blind, controlled, multicentre clinical trial","volume":"19","author":"Hofner","year":"2000","journal-title":"Neurourology & Urodynamics"},{"issue":"5","key":"10.1002\/14651858.CD005429-BIB36|cit36","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1471-0528.1989.tb03263.x","article-title":"Oxybutynin versus propantheline in the management of detrusor instability. A patient-regulated variable dose trial","volume":"96","author":"Holmes","year":"1989","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1002\/14651858.CD005429-BIB37|cit37","series-title":"Proceedings of the International Continence Society (ICS), 32rd Annual Meeting, 28-30 Aug, Heidelberg, Germany","article-title":"Clinical efficacy and safety of tolterodine extended release for treatment of overactive bladder. A phase III, 12-week, randomised, double-blind, placebo and active (oxybutynin) controlled study in Japan and Korea (Abstract 221)","author":"Homma","year":"2002"},{"issue":"1","key":"10.1002\/14651858.CD005429-BIB38|cit38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0301-2115(00)00561-3","article-title":"Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder","volume":"98","author":"Jacquetin","year":"2001","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology"},{"issue":"1","key":"10.1002\/14651858.CD005429-BIB39|cit39","first-page":"S 30","article-title":"Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity (Abstract)","volume":"8","author":"Jacquetin","year":"1997","journal-title":"International Urogynecolgy Journal and Pelvic Floor Dysfunction"},{"issue":"2","key":"10.1002\/14651858.CD005429-BIB41|cit40","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/BF02201987","article-title":"Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation","volume":"15","author":"Jonas","year":"1997","journal-title":"World Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD005429-BIB40|cit41","first-page":"477","article-title":"Efficacy and safety of two doses of tolterodine compared to placebo in patients with detrusor overactivity (Abstract)","volume":"16","author":"Jonas","year":"1997","journal-title":"Neurourology and Urodynamics"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB42|cit42","first-page":"375","article-title":"Placebo-controlled, randomised, double-blind, multicentre clinical trial on the efficacy and tolerability of 1 x 40 mg and 2 x 40 mg trospium chloride (spasmo-lyt) daily for 3 weeks in patients with urge-syndrome (Abstract)","volume":"18","author":"Junemann","year":"1999","journal-title":"Neurourology & Urodynamics"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB43|cit43","first-page":"488","article-title":"Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double-blind, placebo-controlled, multicentre clinical trial (Abstract)","volume":"19","author":"Junemann","year":"2000","journal-title":"Neurourology and Urodynamics"},{"issue":"7","key":"10.1002\/14651858.CD005429-BIB44|cit44","first-page":"256","article-title":"Drug treatment of urgency: a double blind trial of cetiprin\u00ae, dridase\u00ae, urispas\u00ae and placebo","volume":"12","author":"Kramer","year":"1987","journal-title":"TGO tijdschrift voor Therapie, Geneesmiddel, en Onderzoek"},{"key":"10.1002\/14651858.CD005429-BIB45|cit45","series-title":"Proceedings of the International Continence Society (ICS),31st Annual Meeting, 18-21 Sept, Seoul, Korea","article-title":"Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder","author":"Lee","year":"2001"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005429-BIB46|cit46","first-page":"S70","article-title":"A randomized controlled trial of tolterodine versus oxybutynin in the improvement of quality of life for Chinese women suffering from overactive bladder","volume":"12","author":"Leung","year":"2001","journal-title":"International Urogynecology Journal"},{"key":"10.1002\/14651858.CD005429-BIB47|cit47","series-title":"Proceedings of the International Continence Society (ICS), 31st Annual Meeting, 18-21 Sept, Seoul, Korea","article-title":"A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treatment of Chinese women with overactive bladder (Abstract 223)","author":"Leung","year":"2001"},{"key":"10.1002\/14651858.CD005429-BIB48|cit48","series-title":"Proceedings of the 2nd Scientific Meeting of Asian Society for Female Urology, 26-27 Aug, Hong Kong","article-title":"A randomized controlled trial of tolterodine versus oxybutynin in the treatment of overactive bladder in Hong Kong Chinese women (Abstract)","author":"Leung","year":"2000"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB49|cit49","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1464-410X.1995.tb07264.x","article-title":"Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia","volume":"75","author":"Madersbacher","year":"1995","journal-title":"British Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB50|cit50","first-page":"466","article-title":"Trospium chloride versus oxybutynin: a randomized, double-blind, multicenter trial on the treatment of detrusor hyperreflexia (Abstract)","volume":"11","author":"Stohrer","year":"1992","journal-title":"Neurourology & Urodynamics"},{"key":"10.1002\/14651858.CD005429-BIB51|cit51","series-title":"Proceedings of the International Continence Society (ICS), 27th Annual Meeting, 23-26 Sept, Yokohama, Japan","first-page":"153","article-title":"A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin","author":"Madersbacher","year":"1997"},{"key":"10.1002\/14651858.CD005429-BIB52|cit52","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1464-410x.1999.00251.x","article-title":"A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence","volume":"84","author":"Madersbacher","year":"1999","journal-title":"British Journal of Urology International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005429-BIB53|cit53","first-page":"S46","article-title":"Propiverine in patients with urgency and urge incontinence - A placebo controlled, multicenter study comparing its tolerability and efficacy with oxybutynin [Abstract]","volume":"11","author":"Halaska","year":"2000","journal-title":"International Urogynaecology Journal"},{"key":"10.1002\/14651858.CD005429-BIB54|cit54","series-title":"Proceedings of the International Continence Society (ICS), 27th Annual Meeting, 23-26 Sept, Yokohama, Japan","first-page":"155","article-title":"The safety and clinical efficacy of two doses of Tolerodine, compared to placebo in elderly patients","author":"Malone-Lee","year":"1997"},{"issue":"6","key":"10.1002\/14651858.CD005429-BIB55|cit55","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1046\/j.1532-5415.2001.49144.x","article-title":"Tolterodine: a safe and effective treatment for older patients with overactive bladder","volume":"49","author":"Malone-Lee","year":"2001","journal-title":"Journal of the American Geriatric Society"},{"issue":"5","key":"10.1002\/14651858.CD005429-BIB56|cit56","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0022-5347(05)66326-4","article-title":"Tolterodine: superior tolerability and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial","volume":"165","author":"Malone-Lee","year":"2001","journal-title":"Journal of Urology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005429-BIB57|cit57","first-page":"S78","article-title":"Treatment with tolterodine significantly improves social function and energy in patients with overactive bladder","volume":"10","author":"Malone-Lee","year":"1999","journal-title":"International Urogynecology Journal and Pelvic Floor Dysfunction"},{"issue":"2","key":"10.1002\/14651858.CD005429-BIB58|cit58","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1464-410X.1986.tb09010.x","article-title":"Dose titration in clinical trials. An example using emepronium carrageenate in detrusor instability","volume":"58","author":"Massey","year":"1986","journal-title":"British Journal of Urology"},{"key":"10.1002\/14651858.CD005429-BIB59|cit59","series-title":"Proceedings of the International Continence Society (ICS), 14th Annual Meeting, Sept, Innsbruck, Austria","first-page":"109","article-title":"Dose-titrated emepronium carrageenate for detrusor instability","author":"Massey","year":"1984"},{"issue":"3","key":"10.1002\/14651858.CD005429-BIB60|cit60","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/00365599509180578","article-title":"Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence","volume":"29","author":"Mazur","year":"1995","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD005429-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0022-5347(05)68951-3","article-title":"Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity","volume":"161","author":"Millard","year":"1999","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD005429-BIB62|cit62","first-page":"S129","article-title":"A randomized controlled multicentre trial of Tolterodine in detrusor instability\/hyperreflexia (Abstract)","volume":"8","author":"Moore","year":"1997","journal-title":"International Urogynecolgy Journal and Pelvic Floor Dysfunction"},{"issue":"Suppl 167","key":"10.1002\/14651858.CD005429-BIB63|cit63","first-page":"24","article-title":"The clinical efficacy and safety of two doses of Tolterodine in detrusor instability (Abstract)","volume":"5","author":"Rosamilia","year":"1997","journal-title":"Acta Obstetrica et Gynecologica Scandinavica"},{"key":"10.1002\/14651858.CD005429-BIB64|cit64","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/(SICI)1520-6777(1997)16:6<533::AID-NAU3>3.0.CO;2-F","article-title":"Comparison of a 10mg controlled release oxybutynin tablet with a 5mg oxybutynin tablet in urge incontinent patients","volume":"16","author":"Nilsson","year":"1997","journal-title":"Neurourology and Urodynamics"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005429-BIB65|cit65","first-page":"12","article-title":"Trospium chloride versus oxybutynin in the treatment of bladder neurological disorders: A double blind randomized clinical trial (Abstract)","volume":"80","author":"Osca","year":"1997","journal-title":"British Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD005429-BIB66|cit66","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1464-410x.1998.00501.x","article-title":"Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study","volume":"81","author":"Rentzhog","year":"1998","journal-title":"British Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD005429-BIB67|cit67","first-page":"460","article-title":"Long term outcome of women with detrusor instability treated with oxybutynin (Abstract)","volume":"14","author":"Salvatore","year":"1995","journal-title":"Neurourology & Urodynamics"},{"key":"10.1002\/14651858.CD005429-BIB68|cit68","series-title":"Proceedings of the International Continence Society (ICS), 32nd Annual Meeting, 28-30 August, Heidelberg, Germany","article-title":"Efficacy and tolerance of propiverine in neurogenic detrusor overactivity in comparison with oxybutynin (Abstract 341)","author":"Stohrer","year":"2002"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB69|cit69","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1185\/030079902125000570","article-title":"Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET)","volume":"18","author":"Sussman","year":"2002","journal-title":"Current Medical Research and Opinions"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB71|cit70","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0022-5347(17)38459-8","article-title":"Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline verus placebo","volume":"145","author":"Thuroff","year":"1991","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB70|cit71","first-page":"337","article-title":"Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity : oxybutynin vs. propantheline vs. placebo (Abstract)","volume":"9","author":"Thuroff","year":"1990","journal-title":"Neurourology and Urodynamics"},{"issue":"5","key":"10.1002\/14651858.CD005429-BIB72|cit72","first-page":"478","article-title":"Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder","volume":"16","author":"Kerrebroeck","year":"1997","journal-title":"Neurourology & Urodynamics"},{"key":"10.1002\/14651858.CD005429-BIB73|cit73","series-title":"Proceedings of the International Continence Society (ICS), 25th Annual Meeting, 17-20 October, Sydney, Australia","first-page":"95","article-title":"Urodynamic aspects of the efficacy of tolterodine; a new anti muscarine drug in the treatment of detrusor hyperreflexia","author":"Messelink","year":"1995"},{"key":"10.1002\/14651858.CD005429-BIB74|cit74","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<499::AID-NAU6>3.0.CO;2-8","article-title":"Dose-ranging study of tolterodine in patients with detrusor hyperreflexia","volume":"17","author":"Kerrebroeck","year":"1998","journal-title":"Neurourology and Urodynamics"},{"issue":"2","key":"10.1002\/14651858.CD005429-BIB75|cit75","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00044011-200019020-00001","article-title":"Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms","volume":"19","author":"Chancellor","journal-title":"Clinical Drug Investigation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005429-BIB76|cit76","first-page":"S18","article-title":"Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (Abstract)","volume":"12","author":"Garely","year":"2001","journal-title":"International Urology Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005429-BIB79|cit77","first-page":"S94","article-title":"Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder (Abstract)","volume":"11","author":"Kelleher","year":"2000","journal-title":"International Urogynecology Journal"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB77|cit78","first-page":"504","article-title":"Long-term health-related quality of life of patients with overactive bladder receiving tolterodine (Abstract number 82)","volume":"20","author":"Kelleher","year":"2001","journal-title":"Neurourology & Urodynamics"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB78|cit79","first-page":"519","article-title":"Health related quality of life of patients with overactive bladder receiving tolterodine once-daily (Abstract)","volume":"19","author":"Kelleher","year":"2000","journal-title":"Neurourology & Urodynamics"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD005429-BIB80|cit80","first-page":"S165","article-title":"Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders (Abstract)","volume":"165","author":"Kreder","year":"2001","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD005429-BIB81|cit81","series-title":"ICS Abstracts Seoul","first-page":"Abstract number","article-title":"Clinical effectiveness of antimuscarinic therapy : the relationship between efficacy and tolerability","author":"Kreder","year":"2001"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005429-BIB82|cit82","first-page":"S4","article-title":"Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder (Abstract)","volume":"12","year":"2001","journal-title":"International Urogynecolgy Journal"},{"key":"10.1002\/14651858.CD005429-BIB84|cit83","series-title":"Proceedings of the International Continence Society (ICS), 31st Annual Meeting, 18-21 Sept, Seoul, Korea","article-title":"Efficacy and tolerability of once-daily tolterodine for women with overactive bladder (Abstract 329)","author":"Swift","year":"2001"},{"key":"10.1002\/14651858.CD005429-BIB85|cit84","series-title":"Proceedings of the 2nd International Consultation on Incontinence, 1-3 July, Paris","article-title":"Once-daily tolterodine is effective and well tolerated in women with overactive bladder (Abstract 57)","author":"Swift","year":"2001"},{"key":"10.1002\/14651858.CD005429-BIB83|cit85","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00192-002-1009-0","article-title":"A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder","volume":"14","author":"Swift","year":"2003","journal-title":"International Urogynecology Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005429-BIB86|cit86","first-page":"S15","article-title":"Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB) (Abstract)","volume":"11","author":"Swift","year":"2000","journal-title":"International Urogynecolgy Journal"},{"key":"10.1002\/14651858.CD005429-BIB87|cit87","first-page":"40","article-title":"Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with oveactive bladder (Abstract)","volume":"Book 1","author":"Swift","year":"2000","journal-title":"Proceedings of the XVI FIGO World Congress of Obstetrics and Gynaecology, 3-8 Sept, Washington DC"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005429-BIB88|cit88","first-page":"S71","article-title":"Overactive bladder in females: treatment with once-daily Tolterodine (Abstract)","volume":"12","author":"Swift","year":"2001","journal-title":"International Urogynecolgy Journal and Pelvic Floor Dysfunction"},{"key":"10.1002\/14651858.CD005429-BIB89|cit89","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder","volume":"57","author":"Kerrebroeck","year":"2001","journal-title":"Urology"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB90|cit90","first-page":"401","article-title":"Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder (Abstract)","volume":"20","author":"Kerrebroeck","year":"2001","journal-title":"Neurourology and Urodynamics"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005429-BIB91|cit91","first-page":"S49","article-title":"Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OB) (Abstract)","volume":"12","author":"Kerrebroeck","year":"2001","journal-title":"International Urogynecology Journal"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB92|cit92","first-page":"493","article-title":"Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder [Abstract]","volume":"19","author":"Kerrebroeck","year":"2000","journal-title":"Neurourology and Urodynamics"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB93|cit93","first-page":"376","article-title":"Comparison of urge incontinence treatments","volume":"18","author":"Appell","year":"1999","journal-title":"Neurourolgy & Urodynamics"},{"issue":"5","key":"10.1002\/14651858.CD005429-BIB94|cit94","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0029-7844(99)00661-4","article-title":"Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence","volume":"95","author":"Versi","year":"2000","journal-title":"Obstetrics & Gynecology"},{"key":"10.1002\/14651858.CD005429-BIB95|cit95","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-2008-1060401","article-title":"Treatment of bladder unstability and urge incontinence with propiverine hydrochloride (Mictonorm\u00ae) and oxybutynin chloride (Dridase\u00ae) - a randomised cross-over study","volume":"23","author":"Wehnert","year":"1992","journal-title":"Aktuelle Urologie"},{"key":"10.1002\/14651858.CD005429-BIB96|cit96","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00326777","article-title":"Conservative therapy of frequency, urgency and urge incontinence: a double-blind clinical trial of flavoxate hydrochloride, oxybutynin chloride, emepronium bromide and placebo","volume":"5","author":"Zeegers","year":"1987","journal-title":"World Journal of Urology"},{"issue":"Suppl 6A","key":"10.1002\/14651858.CD005429-BIB97|cit97","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0090-4295(97)00599-2","article-title":"Clinical efficacy and safety of tolterodine in the treatment of overactive bladder : a pooled analysis","volume":"50","author":"Appell","year":"1997","journal-title":"Urology"},{"key":"10.1002\/14651858.CD005429-BIB98|cit98","series-title":"Proceedings of the International Incontinence Society (ICS), 8th Annual Meeting","first-page":"67","article-title":"A comparison of flavoxate hydrochloride, emepronium bromide and propantheline for the treatment of female urinary incontinence due to bladder instability","author":"Gaudenz","year":"1978"},{"issue":"5","key":"10.1002\/14651858.CD005429-BIB99|cit99","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0090-4295(98)00629-3","article-title":"Tolterodine in the treatment of overactive bladder : analysis of the pooled phase II efficacy and safety data","volume":"53","author":"Larsson","year":"1999","journal-title":"Urology"},{"key":"10.1002\/14651858.CD005429-BIB100|cit100","series-title":"Proceedings of the International Continence Society (ICS), 31st Annual Meeting, Seoul, Korea","article-title":"Darifenacin, the first selective M3 antagonist for overactive bladder: comparison with oxybutynin on ambulatory monitoring and salivary flow","author":"Mundy","year":"2001"},{"key":"10.1002\/14651858.CD005429-BIB101|cit101","series-title":"Proceedings of the International Continence Society (ICS), 25th Annual Meeting, 17-20 Oct, Sydney, Australia","first-page":"223","article-title":"A double-blind placebo controlled crossover study of the effects of single doses of darifenacin on cystometric parameters in patients with detrusor instability","author":"Rosario","year":"1995"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB102|cit102","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1046\/j.1464-410x.2000.00520.x","article-title":"Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of a multicentre, randomized controlled trial","volume":"85","author":"Tincello","year":"2000","journal-title":"British Journal of Urology International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005429-BIB104|cit103","first-page":"S150","article-title":"A comparison of the efficacy response profile of tolterodine and oxybutynin","volume":"10","author":"Wein","year":"1999","journal-title":"International Urogynecology Journal and Pelvic Floor Dysfunction"},{"key":"10.1002\/14651858.CD005429-BIB103|cit104","series-title":"Proceedings of the International Continence Society (ICS), 29th Annual Meeting, 22-26 Aug, Denver, Colorado","article-title":"A comparison of the efficacy response profile of tolterodine and oxybutynin","author":"Wein","year":"1999"},{"key":"10.1002\/14651858.CD005429-BIB105|cit105","series-title":"Proceedings of the International Continence Society Meeting (ICS), 31st Annual Meeting, 18-21 Sept, Seoul, Korea","article-title":"Comparative efficacy and tolerability between propiverine and oxybutynin in patients with overactive bladder (Abstract 137)","author":"Yoon","year":"2001"},{"issue":"5","key":"10.1002\/14651858.CD005429-BIB106|cit106","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/nau.1930070502","article-title":"Standardisation of terminology of lower urinary tract function","volume":"7","author":"Abrams","year":"1988","journal-title":"Neurourology & Urodynamics"},{"issue":"2","key":"10.1002\/14651858.CD005429-BIB107|cit107","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourology and Urodynamics"},{"key":"10.1002\/14651858.CD005429-BIB108|cit108","unstructured":"Alderson P Green S Higgins JPT Cochrane Reviewers' Handbook 4.2.2 [updated March 2004] Available from: http:www.cochrane.org\/resouces\/handbook\/hbook.htm(accessed 20\/04\/2004)"},{"issue":"6","key":"10.1002\/14651858.CD005429-BIB109|cit109","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4065\/78.6.696","article-title":"Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in health subjects","volume":"78","author":"Appell","year":"2003","journal-title":"Mayo Clinic Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD005429-BIB110|cit110","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0029-7844(99)00263-X","article-title":"Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart & Estrogen\/Progestin Replacement Study (HERS) Research Group","volume":"94","author":"Brown","year":"1999","journal-title":"Obstetrics & Gynecology"},{"key":"10.1002\/14651858.CD005429-BIB111|cit111","series-title":"Proceedings of the International Continence Society (ICS), 31st Annual Meeting, Seoul, Korea","article-title":"The prevalence of overactive bladder in Korea","author":"Choo","year":"2001"},{"issue":"2","key":"10.1002\/14651858.CD005429-BIB112|cit112","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003190.pub2","article-title":"Anticholinergic drugs versus other medications for overactive bladder syndrome in adults","author":"Dublin","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005429-BIB113|cit113","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0029-7844(02)02238-X","article-title":"Drug therapy of urinary urge incontinence: A systematic review","volume":"100","author":"Haeusler","year":"2002","journal-title":"Obstetrics and Gynecology"},{"issue":"1","key":"10.1002\/14651858.CD005429-BIB114|cit114","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1067\/mob.2001.116371","article-title":"Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: A meta-analysis","volume":"185","author":"Harvey","year":"2001","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"15","key":"10.1002\/14651858.CD005429-BIB115|cit115","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.2165\/00003495-200464150-00003","article-title":"Drug treatment of overactive bladder. Efficacy, cost and quality-of-life considerations","volume":"64","author":"Hashim","year":"2004","journal-title":"Drugs"},{"issue":"3","key":"10.1002\/14651858.CD005429-BIB116|cit116","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003781","article-title":"Anticholinergic drugs versus placebo for overactive bladder syndrome in adults","author":"Hay-Smith","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD005429-BIB117|cit117","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s004150050508","article-title":"Urinary, faecal and sexual dysfunction in patients with multiple sclerosis","volume":"246","author":"Hennessey","year":"1999","journal-title":"Journal of Neurology"},{"issue":"Suppl 6A","key":"10.1002\/14651858.CD005429-BIB118|cit118","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0090-4295(97)00580-3","article-title":"The patient with an overactive bladder - symptoms and quality of life issues","volume":"50","author":"Jackson","year":"1997","journal-title":"Urology"},{"issue":"6A suppl","key":"10.1002\/14651858.CD005429-BIB119|cit119","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0090-4295(97)00602-X","article-title":"Economic considerations and outcome measurement in urge incontinence","volume":"50","author":"Kobelt","year":"1997","journal-title":"Urology"},{"issue":"9","key":"10.1002\/14651858.CD005429-BIB120|cit120","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"British Journal of Urology International"},{"issue":"4","key":"10.1002\/14651858.CD005429-BIB121|cit121","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/j.1600-0412.2000.079004298.x","article-title":"The prevalence and bothersomeness of lower urinary tract symptoms in women 40-60 years of age","volume":"79","author":"Moller","year":"2000","journal-title":"Acta Obstetrica et Gynecologica Scandinavica"},{"key":"10.1002\/14651858.CD005429-BIB122|cit122","series-title":"Proceedings of the International Continence Society (ICS), 31st Annual Meeting, Seoul, Korea","article-title":"Prevalence of overactive bladder in Asian males: an epidemiologic survey","author":"Moothy","year":"2001"},{"issue":"10","key":"10.1002\/14651858.CD005429-BIB123|cit123","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/jama.1982.03330100032026","article-title":"Urinary incontinence in elderly nursing home patients","volume":"248","author":"Ouslander","year":"1982","journal-title":"Journal of the American Medical Association"},{"issue":"7","key":"10.1002\/14651858.CD005429-BIB124|cit124","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1532-5415.1986.tb04242.x","article-title":"Genitourinary dysfunction in a geriatric outpatient population","volume":"34","author":"Ouslander","year":"1986","journal-title":"Journal of the American Geriatric Society"},{"issue":"2","key":"10.1002\/14651858.CD005429-BIB125|cit125","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003193.pub2","article-title":"Anticholinergic drug versus non-drug active therapies for overactive bladder syndrome in adults","author":"Patrick","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005429-BIB126|cit126","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF00451721","article-title":"Health related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory","volume":"3","author":"Shumaker","year":"1994","journal-title":"Quality of Life Research"},{"issue":"3","key":"10.1002\/14651858.CD005429-BIB127|cit127","first-page":"S66","article-title":"Prevalence of overactive bladder in women: results from the Noble Program","volume":"12","author":"Stewart","year":"2001","journal-title":"International Urogynecology Journal"},{"issue":"3","key":"10.1002\/14651858.CD005429-BIB128|cit128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.1442-2042.2000.00147.x","article-title":"Urinary incontinence among community-dwelling people aged 40 years or older in Japan: prevalence, risk factors, knowledge and self-perception","volume":"7","author":"Ueda","year":"2000","journal-title":"International Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD005429-BIB129|cit129","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001308.pub2","article-title":"Bladder training for urinary incontinence in adults","author":"Wallace","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005429-BIB130|cit130","volume-title":"SF-36 Health survey manual and interpretation guide","author":"Ware","year":"1993"}],"updated-by":[{"DOI":"10.1002\/14651858.cd005429.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T00:00:00Z","timestamp":1326844800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD005429\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:49:14Z","timestamp":1628531354000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005429"}},"subtitle":[],"editor":[{"given":"Jean","family":"Hay-Smith","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2005,7,20]]},"references-count":130,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005429","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD005429.pub2","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2005,7,20]]}}}